- Highly active RRMS and ocrelizumab after failure of alemtuzumab therapy2020 | Faculty of Medicine in Hradec Králové
- A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients2016 | First Faculty of Medicine
- Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study2016 | First Faculty of Medicine
- Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison2014 | First Faculty of Medicine
- Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis2014 | First Faculty of Medicine
- Deep Gray Matter Iron Content in Neuromyelitis Optica and Multiple Sclerosis2020 | First Faculty of Medicine
- Survey of diagnostic and treatment practices for multiple sclerosis in Europe2017 | First Faculty of Medicine
- Uptake and Effectiveness of Risk-Reducing Surgeries in Unaffected Female BRCA1 and BRCA2 Carriers: A Single Institution Experience in the Czech Republic2023 | First Faculty of Medicine
- Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM2013 | First Faculty of Medicine
- The impact of healthcare systems on the clinical diagnosis and disease-modifying treatment usage in relapse-onset multiple sclerosis: a real-world perspective in five registries across Europe2023 | First Faculty of Medicine
- Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis2023 | First Faculty of Medicine
- Dimethyl-fumarate in treating relapsing-remitting multiple sclerosis +12014 | Second Faculty of Medicine
- Dimethyl fumarate in treating relapsing-remittin multiple sclerosis2015 | First Faculty of Medicine, Second Faculty of Medicine
- Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon beta-1a in MS2016 | First Faculty of Medicine
- Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?2017 | First Faculty of Medicine
- Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring2011 | First Faculty of Medicine
- Evolution of cortical and thalamus atrophy and disability progression in early relapsing-remitting MS during 5 years2013 | First Faculty of Medicine
- Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod2018 | First Faculty of Medicine
- The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing-Remitting and Secondary Progressive Multiple Sclerosis2023 | First Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Subcortical and Cortical Gray Matter Atrophy in a Large Sample of Patients with Clinically Isolated Syndrome and Early Relapsing-Remitting Multiple Sclerosis2012 | First Faculty of Medicine
- Predictors of treatment switching in the Big Multiple Sclerosis Data Network2023 | First Faculty of Medicine
- Pathological cut-offs of global and regional brain volume loss in multiple sclerosis2019 | First Faculty of Medicine
- Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity2023 | First Faculty of Medicine
- Ocrelizumab - pharmacoloical profile2018 | Faculty of Medicine in Pilsen
- Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis A phase 2 study2014 | First Faculty of Medicine
- How does fingolimod (gilenya(R)) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?2013 | First Faculty of Medicine
- Comparative efficacy of first-line natalizumab vs IFN-Beta or glatiramer acetate in relapsing MS2016 | First Faculty of Medicine
- Bimonthly Evolution of Cortical Atrophy in Early Relapsing-Remitting Multiple Sclerosis over 2 Years : A Longitudinal Study2013 | First Faculty of Medicine
- Alemtuzumab long-term immunologic effect Treg suppressor function increases up to 24 months2016 | First Faculty of Medicine